Is Can-Fite BioPharma Ltd. building a differentiated niche in late-line pancreatic cancer therapy
Is Can-Fite BioPharma Ltd. carving a niche in pancreatic cancer? Explore how namodenoson’s Phase 2a data could reshape late-line treatment strategies.
Pharma & Biotech